KR20100037309A - Pill type manufacturing method of health supporting food - Google Patents
Pill type manufacturing method of health supporting food Download PDFInfo
- Publication number
- KR20100037309A KR20100037309A KR1020080096569A KR20080096569A KR20100037309A KR 20100037309 A KR20100037309 A KR 20100037309A KR 1020080096569 A KR1020080096569 A KR 1020080096569A KR 20080096569 A KR20080096569 A KR 20080096569A KR 20100037309 A KR20100037309 A KR 20100037309A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- lactic acid
- acid bacteria
- vitamin
- dried
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 28
- 235000013305 food Nutrition 0.000 title claims description 21
- 230000036541 health Effects 0.000 title abstract description 11
- 239000006187 pill Substances 0.000 title abstract 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 165
- 241000894006 Bacteria Species 0.000 claims abstract description 115
- 239000004310 lactic acid Substances 0.000 claims abstract description 82
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 82
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 26
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 26
- 244000068988 Glycine max Species 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 22
- 241000241413 Propolis Species 0.000 claims abstract description 18
- 229940069949 propolis Drugs 0.000 claims abstract description 18
- 241000186660 Lactobacillus Species 0.000 claims abstract description 17
- 244000046052 Phaseolus vulgaris Species 0.000 claims abstract description 17
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 17
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 17
- 239000004475 Arginine Substances 0.000 claims abstract description 16
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 15
- 240000000759 Lepidium meyenii Species 0.000 claims abstract description 14
- 235000010447 xylitol Nutrition 0.000 claims abstract description 14
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000000421 Lepidium meyenii Nutrition 0.000 claims abstract description 13
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 13
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000012902 lepidium meyenii Nutrition 0.000 claims abstract description 13
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 13
- 239000011718 vitamin C Substances 0.000 claims abstract description 13
- 239000000811 xylitol Substances 0.000 claims abstract description 13
- 229960002675 xylitol Drugs 0.000 claims abstract description 13
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 13
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 12
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 12
- 239000011710 vitamin D Substances 0.000 claims abstract description 12
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 12
- 229940046008 vitamin d Drugs 0.000 claims abstract description 12
- 230000000968 intestinal effect Effects 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 10
- 241001474374 Blennius Species 0.000 claims description 36
- 235000015872 dietary supplement Nutrition 0.000 claims description 32
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 20
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 18
- 229960002477 riboflavin Drugs 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 229930003471 Vitamin B2 Natural products 0.000 claims description 16
- 235000019164 vitamin B2 Nutrition 0.000 claims description 16
- 239000011716 vitamin B2 Substances 0.000 claims description 16
- 229960003495 thiamine Drugs 0.000 claims description 15
- 229930003451 Vitamin B1 Natural products 0.000 claims description 13
- 235000010374 vitamin B1 Nutrition 0.000 claims description 13
- 239000011691 vitamin B1 Substances 0.000 claims description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 12
- 239000011575 calcium Substances 0.000 claims description 12
- 229910052791 calcium Inorganic materials 0.000 claims description 12
- 235000008390 olive oil Nutrition 0.000 claims description 10
- 239000004006 olive oil Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 8
- 235000013373 food additive Nutrition 0.000 claims description 7
- 239000002778 food additive Substances 0.000 claims description 7
- 235000021332 kidney beans Nutrition 0.000 claims description 7
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 6
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 235000009499 Vanilla fragrans Nutrition 0.000 claims description 5
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims description 5
- 240000007594 Oryza sativa Species 0.000 claims description 4
- 235000007164 Oryza sativa Nutrition 0.000 claims description 4
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 4
- 235000013339 cereals Nutrition 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 235000009566 rice Nutrition 0.000 claims description 4
- 244000290333 Vanilla fragrans Species 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- 238000004898 kneading Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 abstract description 11
- 239000011812 mixed powder Substances 0.000 abstract description 6
- 229930003270 Vitamin B Natural products 0.000 abstract description 3
- 239000008371 vanilla flavor Substances 0.000 abstract description 3
- 229940088594 vitamin Drugs 0.000 abstract description 3
- 229930003231 vitamin Natural products 0.000 abstract description 3
- 235000013343 vitamin Nutrition 0.000 abstract description 3
- 239000011782 vitamin Substances 0.000 abstract description 3
- 235000019156 vitamin B Nutrition 0.000 abstract description 3
- 239000011720 vitamin B Substances 0.000 abstract description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 abstract description 2
- 239000002028 Biomass Substances 0.000 abstract 2
- 241000199919 Phaeophyceae Species 0.000 abstract 1
- 241000047339 Salicornia brachystachya Species 0.000 abstract 1
- 229960002079 calcium pantothenate Drugs 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 17
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- 210000000936 intestine Anatomy 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 235000005152 nicotinamide Nutrition 0.000 description 8
- 239000011570 nicotinamide Substances 0.000 description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 230000006835 compression Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 244000061456 Solanum tuberosum Species 0.000 description 5
- 235000002595 Solanum tuberosum Nutrition 0.000 description 5
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 235000013325 dietary fiber Nutrition 0.000 description 5
- 229960002061 ergocalciferol Drugs 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 235000001892 vitamin D2 Nutrition 0.000 description 5
- 239000011653 vitamin D2 Substances 0.000 description 5
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 5
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 5
- 235000005282 vitamin D3 Nutrition 0.000 description 5
- 239000011647 vitamin D3 Substances 0.000 description 5
- 229940021056 vitamin d3 Drugs 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 235000003276 Apios tuberosa Nutrition 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000257303 Hymenoptera Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 201000010538 Lactose Intolerance Diseases 0.000 description 3
- 241001300423 Strophostyles Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 244000263375 Vanilla tahitensis Species 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000012015 potatoes Nutrition 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 2
- -1 Anoline Chemical compound 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000002141 Pellagra Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 235000021092 sugar substitutes Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000554155 Andes Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 244000001666 Phaseolus vulgaris var. humilis Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000015177 Saccharina japonica Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241000264279 Sargassum fusiforme Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241001261506 Undaria pinnatifida Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241001464837 Viridiplantae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 108010066657 azoreductase Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940068140 lactobacillus bifidus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100001223 noncarcinogenic Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000014639 sexual reproduction Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000010981 turquoise Substances 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
이 발명은 유산균을 이용한 환형 건강보조식품을 제조하는 방법에 관한 것으로, 환형 건강보조식품은 동결 건조된 혼합유산균 사균체를 혼합한 유산균 혼합체, 프로폴리스, 비타민 B1, 비타민 B2, 비타민 D, 비타민 C, 자일리톨, 니코틴산아미드, 아르기닌, 바닐라후레바, 펜토텐산칼슘, 함초, 강낭콩, 자연산 야생콩(Glycine soja), 건미역, 건다시마, 건톳, 단백질로 코팅된 동결건조 비피더스 균, 마카를 리본믹서기로 200 메쉬의 크기로 균질 혼합하고 정제화함으로서 완성된다. 바람직하게는 동결 건조된 혼합유산균 사균체를 혼합한 유산균 혼합체 0.1 중량%, 프로폴리스 2 중량%, 비타민 B1 0.1 중량%, 비타민 B2 0.1 중량%, 비타민 D 0.1 중량%, 비타민 C 0.3 중량%, 자일리톨 5 중량%, 니코틴산아미드 0.3 중량%, 아르기닌 0.3 중량%, 바닐라후레바 0.2 중량%, 펜토텐산칼슘 0.1 중량%, 함초 3 중량%, 강낭콩 66.3 중량%, 자연산 야생콩(Glycine soja) 5 중량%, 건미역 5 중량%, 건다시마 5 중량%, 건 톳 2 중량%, 단백질로 코팅된 동결건조 비피더스 균 0.1 중량%, 마카 5 중량%를 리본믹서기로 200 메쉬의 크기로 균질 혼합분말을 제조하고, 여기에 또 다 시 물, 올리브유 등의 액체를 투여하여 반죽하고, 이를 압축 장환기, 제환기, 정환기, 건조기에 순서의 과정을 거쳐 제조된다.The present invention relates to a method of manufacturing a circular dietary supplement using lactic acid bacteria, the circular dietary supplement is a lactic acid bacteria mixture mixed with lyophilized mixed lactic acid bacteria, propolis, vitamin B1, vitamin B2, vitamin D, vitamin C , Xylitol, nicotinic acid amide, arginine, vanilla flavor, calcium pentothenate, seaweed, kidney bean, wild soybean (Glycine soja), dried seaweed, dried seaweed, dried fish, protein coated with lyophilized bifidus, maca with ribbon mixer Complete by homogeneous mixing and tableting to the size of the mesh. Preferably, 0.1% by weight of lactic acid bacteria mixed with lyophilized mixed lactic acid bacteria, 2% by weight of propolis, 0.1% by weight of vitamin B1, 0.1% by weight of vitamin B2, 0.1% by weight of vitamin D, 0.3% by weight of vitamin C, xylitol 5% by weight, 0.3% by weight nicotinamide, 0.3% by weight arginine, 0.2% by weight vanillafureva, 0.1% by weight pentothenate calcium, 3% by weight of seaweed, 66.3% by weight bean, 5% by weight of wild soybean (Glycine soja), 5% by weight of dried seaweed, 5% by weight of dried seaweed, 2% by weight of dried 톳, 0.1% by weight of lyophilized bifidus bacteria coated with protein, and 5% by weight of maca were prepared in a homogeneous mixed powder in a size of 200 mesh using a ribbon mixer. Again, water, olive oil and other liquids are administered and kneaded, and these are manufactured through a sequence of processes in the compression chapter, the recirculator, the recirculator, and the dryer.
건강보조식품이란, 일반적으로 보통의 식품과 비교했을 때 그 성분에 특징이 있어 건강의 유지, 증진에 효과를 기대할 수 있는 식품으로서 의학적으로 인체 건강유지에 효능이 있다고 생각되는 특정 성분을 선택하여 농축, 정제, 혼합, 가공한 식품을 말한다. 의약품은 아니나 질병의 예방과 치료에 대해 기대를 가지고 섭취하는 식품으로 대개 상업적인 의미에서 쓰이고 있다. 우리나라의 경우 차츰 시장규모도 커지고 취급자의 자격, 유통 등에 문제도 생겨, 1987년 당시 보건사회부는 식품위생법을 개정하여 일반인이 부르는 건강식품을 `건강보조식품`이라 명명하였고, 식품공전에 나타나 있는 건강보조 식품의 정의는 “건강보조의 목적으로 특정성분을 원료로 하거나 식품원료에 들어있는 특정성분을 추출, 정제, 혼합 등의 방법으로 제조, 가공한 식품을 말한다.”로 정의되어있다.Health supplements are foods that can be expected to be effective in maintaining and improving health as compared to ordinary foods, and are selected and concentrated by selecting specific ingredients that are considered to be effective in maintaining human health. , Refined, mixed, processed foods. It is not a medicinal product but a food consumed in anticipation of the prevention and treatment of diseases, and is usually used in a commercial sense. In Korea, the size of the market gradually grew and problems with the qualifications and distribution of handlers occurred.In 1987, the Ministry of Health and Social Affairs revised the Food Sanitation Law to name health foods called 'health supplements'. The definition of supplements is defined as "foods prepared and processed by extracting, refining, or mixing certain ingredients as raw materials or contained in food ingredients for the purpose of health assistance."
유산균을 이용한 건강보조식품과 관련한 보고는 다수 존재한다. 유산균을 섭취하면 우리 몸에서 기대할 수 있는 효과로는 다음과 같은 효과가 있는 것으로 알려져 있다.There are many reports regarding dietary supplements using lactic acid bacteria. Ingesting lactic acid bacteria is expected to have the following effects in our bodies.
앞에서도 살펴보았듯이, 건강보조식품은 의약과는 달리 그 성분에 특징이 있어 건강의 유지, 증진에 효과를 기대할 수 있는 식품으로서 의학적으로 인체 건강유지에 효능이 있다고 생각되는 특정 성분을 선택하여 농축, 정제, 혼합, 가공한 식품을 말한다. As we have seen, health supplement foods, unlike medicines, are characterized by their ingredients and can be expected to be effective in maintaining and improving health. They are concentrated by selecting specific ingredients that are considered medically effective for maintaining human health. , Refined, mixed, processed foods.
기지의 건강보조식품에는 여러 가지 종류의 보고가 많고 유산균을 포함하는 건강보조식품 또한 많이 보고되어 있다. 인류역사가 유제품을 식품으로 선택한 이래 유산균을 섭취하면 장내 미생물 총균에 유익한 효과가 있어 소화가 잘되고 장수할 수 있음을 경험적으로 알고 있었다. 근래에 들어서는 과학의 발달과 더불어 그 유익한 정도를 구체적으로 알 수 있게 되었고, 이를 포함하는 건강식품도 다수 보고되고 있다.There are many reports of various types of health supplements, and many health supplements containing lactic acid bacteria have been reported. Since human history has chosen dairy products as foods, empirically knowing that ingesting lactic acid bacteria has a beneficial effect on the intestinal microflora and can be digested and longevity. In recent years, with the development of science, it is possible to know the beneficial level in detail, and many health foods including this have been reported.
그러나 유산균이 우리 몸에 유익하다는 것은 모두 알았지만, 통상적으로 유산균을 섭취했을 경우 우리의 위에서 분비되는 위산, 소화효소 등에 의하여 섭식된 유산균은 대부분 사멸하여 유산균 섭취의 목적인 소장 또는 대장에서 유산균이 살아갈 수 있도록 하는 데에는 어려움이 있었고, 이를 극복하기 위하여 많은 보고가 있다.However, we all know that lactic acid bacteria are beneficial to our bodies, but when lactic acid bacteria are ingested, most of the lactic acid bacteria eaten by gastric acid and digestive enzymes secreted in our stomach can be killed, so that lactic acid bacteria can live in the small intestine or large intestine, which is the purpose of ingesting lactic acid bacteria. There was a difficulty in making this work, and there are many reports to overcome it.
특허공개공보 제10-2002-0019801호는 유산균을 이용한 발효비지 제조방법을, 특허공개공보 제10-2003-0006690호는 유산균의 정제 코팅장치를, 그리고 특허공개공보 제10-2004-0037011호는 유산균 함유 식품조성물 및 그 제조방법을 보고하고 있는 등, 유산균을 이용한 건강보조식품의 개발과 관련한 다수의 문헌을 찾아 볼 수 있다.Patent Publication No. 10-2002-0019801 discloses a method for producing fermentation bean using lactic acid bacteria, Patent Publication No. 10-2003-0006690 describes a tablet coating apparatus for lactic acid bacteria, and Patent Publication No. 10-2004-0037011 Numerous documents related to the development of dietary supplements using lactic acid bacteria can be found, including reporting on lactic acid bacteria-containing food compositions and methods for their preparation.
그러나 이 발명의 발명자들은 상기 유산균을 함유하는 다양한 발명을 검토하고 실시해본 결과 유산균을 함유하는 건강식품이 제형을 달리했을 경우 그 제형 특이적으로 유산균의 상기 기대되는 효과를 극대화할 수 있는 구성의 조합이 있음을 발견하고 이 발명에 이르게 되었다. 구체적으로 기술하면, 통상의 유산균이 함유된 환형 건강보조식품에는 각각 그 영양학적 이로움이 잘 알려진 식이섬유, 프로폴리스 등을 포함하게 되지만 이 성분들은 유산균의 생육환경을 악화시켜 사람이 섭취했을 경우 결국 그 유효성을 저감시키는 결과가 있었기에, 상기 식이섬유, 프로폴리스 등 각각의 영양 유용성을 방해하지 않으면서도 유산균의 영양학적 유용성을 증가시킬 수 있는 구성의 조합을 검토한 결과 이 발명을 완성하게 되었다.However, the inventors of the present invention have reviewed and practiced various inventions containing lactic acid bacteria, and as a result, when a health food containing lactic acid bacteria had a different formulation, a combination of components that could maximize the expected effect of the specific formulation of the lactic acid bacteria It was found that this led to this invention. Specifically, cyclic health supplements containing conventional lactic acid bacteria include dietary fiber and propolis, each of which is well known for its nutritional benefits, but these components worsen the growth environment of lactic acid bacteria and eventually become ingested by humans. As a result of reducing the effectiveness thereof, the present invention has been completed as a result of examining a combination of components that can increase the nutritional usefulness of lactic acid bacteria without disturbing the nutritional usefulness of each of the above-mentioned dietary fiber and propolis.
따라서 이 발명은 상기 유산균과 더불어 영양학적으로 우수한 조합의 건강보조식품을 제조하는 방법과 이 방법으로 제조되는 건강보조식품을 제공하는 것을 목적으로 한다.Therefore, an object of the present invention is to provide a method for producing a nutritionally excellent combination of dietary supplements with the lactic acid bacteria and a dietary supplement made by the method.
본 발명은 상기와 같은 기술적 과제를 해결하기 위해, 동결 건조된 혼합유산균 사균체를 혼합한 유산균 혼합체 0.1 중량%, 프로폴리스 2 중량%, 비타민 B1 0.1 중량%, 비타민 B2 0.1 중량%, 비타민 D 0.1 중량%, 비타민 C 0.3 중량%, 자일리톨 5 중량%, 니코틴산아미드 0.3 중량%, 아르기닌 0.3 중량%, 바닐라후레바 0.2 중량%, 펜토텐산칼슘 0.1 중량%, 함초 3 중량%, 강낭콩 66.3 중량%, 글리신소야(Glycine soja) 5 중량%, 건미역 5 중량%, 건다시마 5 중량%, 건 톳 2 중량%, 단백질로 코팅된 동결건조 비피더스 균 0.1 중량%, 마카 5 중량%를 리본믹서기로 200 메쉬의 크기로 균질 혼합분말을 제조하고, 여기에 또 다시 물과 올리브유를 투여하여 반죽하고, 이를 압축 장환기, 제환기, 정환기, 건조기를 사용하는 순서의 과정을 거쳐 제조되는 것을 특징으로 한다.The present invention, in order to solve the above technical problem, lactic acid bacteria mixture mixed with lactic acid bacteria microorganisms lyophilized 0.1% by weight, propolis 2% by weight, vitamin B1 0.1% by weight, vitamin B2 0.1% by weight, vitamin D 0.1 Weight%, Vitamin C 0.3%, Xylitol 5%, Nicotinamide 0.3%, Arginine 0.3%, Vanillafureva 0.2%, Calcium Pentothenate 0.1%, Seaweed 3%, Kidney Beans 66.3%, Glycine 5% by weight of Glycine soja, 5% by weight of dried seaweed, 5% by weight of dried seaweed, 2% by weight of dried 톳, 0.1% by weight of lyophilized bifidus coated with protein and 5% by weight of maca with a ribbon mixer To prepare a homogeneous mixed powder, and to knead again by administering water and olive oil to it, it is characterized in that it is prepared through a procedure of using a compressed chapter ringer, a recirculator, a converter, a dryer.
또한, 상기 강낭콩은 물로 세척 후 압력솥에서 100℃ 이상으로 15분간 3번 삶아 증숙시키고, 열풍건조기에서 200℃ 이하의 조건에서 건조하여 분해한 후, 분쇄기에 200메쉬로 분쇄하여 제조되는 것을 특징으로 한다.In addition, the kidney beans are steamed and boiled three times for 15 minutes at 100 ℃ or more in a pressure cooker after washing with water, and dried under the conditions of 200 ℃ or less in a hot air dryer, and decomposed, and then pulverized to 200 mesh in a pulverizer .
또한, 상기 함초는 건조된 함초를 선별하여 이물질을 제거한 후 분쇄기에 200메쉬로 분쇄하여 제조되는 건강보조식품을 제조하는 방법In addition, the seaweed is a method of manufacturing a health supplement food is prepared by pulverizing the dried seaweed to remove foreign substances and then pulverized in 200 mesh
또한, 글리신소야(Glycine soja)는 쌀알 정도의 자연산을 물로 세척한 후 건조하고, 15분가량 4번 정도 삶아서 증숙한 후, 열풍건조기에서 200℃ 이하로 수분 5%이하 건조한 후 분쇄기에 200메쉬로 분쇄하여 제조되는 것을 특징으로 한다.In addition, glycine soja is washed with natural water, such as rice grains, dried with water, boiled four times for about 15 minutes, steamed, and then dried in a hot air dryer at 200 ° C or less for 5% or less of moisture, and then at 200 mesh in a grinder. It is characterized by being manufactured by grinding.
또한, 건미역, 건다시마 또는 건톳은 이물질 제거 후 200메쉬로 분쇄하여 제조되는 것을 특징으로 한다.In addition, dried seaweed, dried kelp or dried fish is characterized in that it is prepared by grinding to 200 mesh after removing the foreign matter.
또한, 상기 제조방법은 식품첨가물이 더 포함될 수 있으며, 이 식품첨가물은 초벌믹서시 혼합하는 것을 특징으로 한다.In addition, the manufacturing method may further include a food additive, the food additive is characterized in that the mixing in the initial mixing.
또한, 건강보조식품의 분쇄물 수분함량이 5%를 초과하지 않는 것을 특징으로 한다. In addition, the moisture content of the pulverized food of the health supplement is characterized in that it does not exceed 5%.
또한, 건강보조식품은 다이어트에 효과가 있는 것을 특징으로 한다.In addition, the dietary supplement is characterized in that it is effective in diet.
이 발명은 기존의 유산균이 포함된 건강보조식품과 비교하여, 유산균의 활성이 우수하며, 섭식한 사람의 장내 환경을 개선하고, 특히 여성에 있어서는 변비를 예방하거나 개선시킬 수 있다. 또한 이 발명의 건강보조식품을 섭식하면, 각 구성이 가지고 있는 영양효과를 더욱 증진시킬 수 있다.Compared with the conventional dietary supplement containing lactic acid bacteria, the present invention is excellent in the activity of lactic acid bacteria, and improves the intestinal environment of the fed people, especially in women can prevent or improve constipation. In addition, by eating a dietary supplement of the present invention, it is possible to further enhance the nutritional effect of each component.
이 발명은 유산균을 이용한 환형 건강보조식품을 제조하는 방법에 관한 것으로, 환형 건강보조식품은 동결 건조된 혼합유산균 사균체를 혼합한 유산균 혼합체, 프로폴리스, 비타민 B1, 비타민 B2, 비타민 D, 비타민 C, 자일리톨, 니코틴산아미드, 아르기닌, 바닐라후레바, 펜토텐산칼슘, 함초, 강낭콩, 자연산 야생콩(Glycine soja), 건미역, 건다시마, 건톳, 단백질로 코팅된 동결건조 비피더스 균, 마카를 리본믹서기로 200 메쉬의 크기로 균질 혼합하고 정제화함으로서 완성된다. 바람직하게는 동결 건조된 혼합유산균 사균체를 혼합한 유산균 혼합체 0.1 중량%, 프로폴리스 2 중량%, 비타민 B1 0.1 중량%, 비타민 B2 0.1 중량%, 비타민 D 0.1 중량%, 비타민 C 0.3 중량%, 자일리톨 5 중량%, 니코틴산아미드 0.3 중량%, 아르기닌 0.3 중량%, 바닐라후레바 0.2 중량%, 펜토텐산칼슘 0.1 중량%, 함초 3 중량%, 강낭콩 66.3 중량%, 자연산 야생콩(Glycine soja) 5 중량%, 건미역 5 중량%, 건다시마 5 중량%, 건 톳 2 중량%, 단백질로 코팅된 동결건조 비피더스 균 0.1 중량%, 마카 5 중량%를 리본믹서기로 200 메쉬의 크기로 균질 혼합분말을 제조하고, 여기에 또 다 시 물, 올리브유 등의 액체를 투여하여 반죽하고, 이를 압축 장환기, 제환기, 정환기, 건조기에 순서의 과정을 거쳐 제조된다.The present invention relates to a method of manufacturing a circular dietary supplement using lactic acid bacteria, the circular dietary supplement is a lactic acid bacteria mixture mixed with lyophilized mixed lactic acid bacteria, propolis, vitamin B1, vitamin B2, vitamin D, vitamin C , Xylitol, nicotinic acid amide, arginine, vanilla flavor, calcium pentothenate, seaweed, kidney bean, wild soybean (Glycine soja), dried seaweed, dried seaweed, dried fish, protein coated with lyophilized bifidus, maca with ribbon mixer Complete by homogeneous mixing and tableting to the size of the mesh. Preferably, 0.1% by weight of lactic acid bacteria mixed with lyophilized mixed lactic acid bacteria, 2% by weight of propolis, 0.1% by weight of vitamin B1, 0.1% by weight of vitamin B2, 0.1% by weight of vitamin D, 0.3% by weight of vitamin C, xylitol 5% by weight, 0.3% by weight nicotinamide, 0.3% by weight arginine, 0.2% by weight vanillafureva, 0.1% by weight pentothenate calcium, 3% by weight of seaweed, 66.3% by weight bean, 5% by weight of wild soybean (Glycine soja), 5% by weight of dried seaweed, 5% by weight of dried seaweed, 2% by weight of dried 톳, 0.1% by weight of lyophilized bifidus bacteria coated with protein, and 5% by weight of maca were prepared in a homogeneous mixed powder in a size of 200 mesh using a ribbon mixer. Again, water, olive oil and other liquids are administered and kneaded, and these are manufactured through a sequence of processes in the compression chapter, the recirculator, the recirculator, and the dryer.
이 발명에서 사용되는 혼합유산균은 시중에서 판매되는 혼합유산균을 구입하여 사용해도 무방하고, 당업자에게 알려진 유산균을 각 종류별로 배양하여 사용하여도 이 발명의 우수한 효과를 보기에 무방하다. 하기는 통상 알려진 유산균의 종류와 수득할 수 있는 방법, 그리고 각 유산균을 배양하는 배지에 관한 정보에 관한 것이다.The mixed lactic acid bacteria used in the present invention may be purchased and used commercially available mixed lactic acid bacteria, and even if the lactic acid bacteria known to those skilled in the art can be cultured and used for each type, it is possible to see the excellent effect of the present invention. The following generally relates to the types of known lactic acid bacteria, methods that can be obtained, and information on the medium for culturing each lactic acid bacteria.
------------------------------------------------------------------------------------------------------------------------------- ---------------------------
Strain Media Strain media
------------------------------------------------------------------------------------------------------------------------------- ---------------------------
Lactobacillus acidophilus ATCC 4356 MRS broth(Defico) Lactobacillus acidophilus ATCC 4356 MRS broth (Defico)
Lactobacillus lactics ATCC 4797 MRS broth(Defico) Lactobacillus lactics ATCC 4797 MRS broth (Defico)
Streptococcus thermophilus KCTC 2185 MRS broth(Defico) Streptococcus thermophilus KCTC 2185 MRS broth (Defico)
Lactobacillus casei IFO 3533 MRS (Defico) Lactobacillus casei IFO 3533 MRS (Defico)
Staphylococcus aureus KFCC 11764 Nutrient broth(Defico) Staphylococcus aureus KFCC 11764 Nutrient broth (Defico)
------------------------------------------------------------------------------------------------------------------------------- ---------------------------
배양된 각 유산균은 사균으로 사용되며, 유산균을 사균으로 만드는 기술은 가열하거나 산을 처리하여 사균체를 만드는 방법이 있으나, 시중에사 판매되는 유산균의 사균체를 구입하여 사용하여도 발명의 목적의 달성에는 아무런 지장이 없 다.Each cultured lactic acid bacteria is used as dead bacteria, and the technique of making lactic acid bacteria is a method of making dead bacteria by heating or treating acid, but it is necessary to purchase and use the dead bacteria of commercially available lactic acid bacteria. There is no obstacle to attainment.
이 발명에서 사용되는 강낭콩은 물로 세척 후 압력솥에서 100℃ 이상으로 15분간 3번 삶고, 증숙시킨다. 그런 다음, 열풍건조기에서 200℃ 이하로 건조 후 분쇄기에서 200메쉬로 분쇄하여 제조되며, 함초는 건조된 함초를 선별하여 이물질을 제거한 후 분쇄기에 200메쉬로 분쇄하여 제조되고, 글리신소야(Glycine soja)는 쌀알 정도의 자연산 콩을 물로 세척한 후 건조하고, 15분가량 4번 정도 삶아서 증숙한 후, 열풍건조기에서 200℃ 이하로 수분 5%이하 건조한 후 분쇄기에 200메쉬로 분쇄하여 제조되는 것이며, 건미역, 건다시마 또는 건톳은 이물질 제거 후 200메쉬로 분쇄하여 제조된다. 그리고 환 제형에 있어 정환기를 사용할 때 올리브유를 미량 더 부가할 수 있는데, 올리브유는 환에 걷 모양을 윤택하게 하는 효과가 있다. 유산균 사균체는 영양학적으로 열에 약하여 제환기, 정환기 등을 사용함에 필히 열을 가하게 되는데, 영양소를 파괴하지 않는 온도, 즉 200℃를 넘지 않는 선에서 기계를 운용할 필요가 있다. 이 온도를 넘어가면 이 발명의 효과가 저감되는 경향을 경험적으로 알 수 있었다.Kidney beans used in the present invention is washed with water and boiled three times for 15 minutes at 100 ℃ or more in a pressure cooker, and steamed. Then, dried to 200 ℃ or less in a hot air dryer after pulverization is prepared by 200 mesh in the pulverizer, the seaweed is prepared by pulverizing to 200 mesh in the pulverizer after removing the foreign matter by selecting the dried seaweed, Glycine soja (Glycine soja) The natural grains of rice grains are washed with water and dried, boiled and steamed for about 15 minutes four times, steamed and dried in a hot air dryer at 200 ° C or less and less than 5% moisture and then pulverized with 200 mesh in a grinder. , Dried seaweed or dried seaweed is prepared by grinding into 200 mesh after removing foreign matter. And in the ring formulation, when the use of the purifier may be added a small amount of olive oil, olive oil has the effect of moistening the shape of the hook to the ring. Lactobacillus microorganisms are nutritionally weak and heat is required to use a recirculator, purifier, etc., it is necessary to operate the machine at a temperature that does not destroy nutrients, that is, not exceeding 200 ℃. Exceeding this temperature has shown empirically the tendency for the effect of this invention to reduce.
이 발명은 식품첨가물이 더 포함될 수 있으며, 이 식품첨가물은 초벌믹서시 혼합하여 제조한다. 또한 전체적으로 이 환형 식품첨가물의 수분함량은 5%를 초과하지 않는다. 이는 사균체를 사용하는 이 발명의 보존기간과 식품첨가물로서의 영양효능을 극대화시키기 위한 필요조건이다.The present invention may further include food additives, which are prepared by mixing the initial mixing. In addition, the water content of this cyclic food additive does not exceed 5%. This is a requirement for maximizing the shelf life and nutritional efficacy of the food additive of the present invention using dead cells.
이 발명의 구성 각각이 가지고 있는 특징을 살펴보면 다음과 같은 특징이 있 다.Looking at the features of each of the configuration of the present invention has the following features.
가. 유산균end. Lactobacillus
이 발명의 유산균은 사균체로서 시중에서 상업적으로 유통되는 물건을 수득하여 사용할 수 있으며, 특허공개공보 제10-2003-0070800호, 제10-1997-0000057호 등에 공개된 방법에 의하여 제조하여 사용하는 것도 가능하다.The lactic acid bacteria of the present invention can be obtained by using commercially available products as commercial bacteria, and prepared and used by methods disclosed in Korean Patent Publication Nos. 10-2003-0070800, 10-1997-0000057, and the like. It is also possible.
1. 장내 유해균 억제 작용 및 정장작용 1. Inhibition of harmful bacteria and intestinal action
장내에 정착한 유산균은 병원성 세균이 소화관 상피에 부착하는 것을 방해하여 질병발생을 막아주며, 유산균에 의해 생성된 항생물질이 설사를 일으키는 병원성 미생물이나 장내 유해균을 죽이거나 증식을 억제한다. Lactobacillus settled in the intestine prevents pathogenic bacteria from adhering to the gut epithelium and prevents the occurrence of disease, and antibiotics produced by lactic acid bacteria kill or inhibit the growth of pathogenic microorganisms or intestinal harmful bacteria.
2. 혈중 콜레스테롤을 감소 2. reduce blood cholesterol
유산균 섭취 시 유산균 발효로 생성되는 HMG(Hydroxy Methyl Glutaric), Orotic Acid, Uric acid 등에 의한 콜레스테롤 생성은 저해되고, 특히 락토바실러스 애시도필러스는 직접 콜레스테롤을 분해하는 기능을 갖는다. 이런 이유로 현대인의 3대 사망원인 중의 하나인 혈관질환으로 인한 심장병, 동맥경화, 고혈압 및 뇌졸중을 예방에 유산균의 섭취는 매우 유익하다. When ingesting lactic acid bacteria, cholesterol production by HMG (Hydroxy Methyl Glutaric), Orotic Acid, Uric acid, etc. produced by fermentation of lactic acid bacteria is inhibited, and in particular, Lactobacillus ashdophilus has a function of directly degrading cholesterol. For this reason, ingestion of lactic acid bacteria is very beneficial in preventing heart disease, arteriosclerosis, hypertension and stroke caused by vascular disease, one of the three leading causes of death in modern people.
3. 면역증강 효과 3. Immune Boosting Effect
면역반응은 초기에 질병을 치유 및 예방하기 위한 인체의 방어 기작이다. 따라서 병원균 감염 시 면역계의 신속한 반응은 질병으로부터 인체를 보호할 수 있다. 유산균은 이러한 면역계에서 병원균의 감지하는 macrophage를 활성화시켜 외부 로부터 유입된 세균 및 바이러스를 신속히 감지하여 임파구 분열을 촉진시키고 혈액 내의 항체인 IgA의 생산을 증가시킨다. 그리고 γ-interferon 생성으로 면역력을 증진시켜 항암 효과까지 나타낸다. The immune response is the body's defense mechanisms for the early healing and prevention of disease. Thus, the rapid response of the immune system during pathogen infection can protect the body from disease. Lactobacillus activates the sensing macrophage of pathogens in this immune system to rapidly detect bacteria and viruses from outside, promote lymphocyte division and increase the production of IgA, an antibody in the blood. And γ-interferon production to enhance immunity to anti-cancer effects.
4. 영양학적 가치 증진 4. Promoting Nutritional Value
유산균들은 발육ㆍ증식하면서 lactic acid를 생성하며, 부산물로 아밀라제, 셀룰라제, 리파제, 프로티아제와 같은 소화효소를 생성하여 음식의 소화흡수를 돕는다. 또한 유산균은 비타민 B1, B2, B6, B12 등을 합성할 뿐만 아니라 비타민 B1을 파괴하는 효소 생산균의 생육을 저해하여 비타민 B군을 안정화시킨다. 또한 유산균이 장내에서 생존하면서 부산물로서 비타민 B군 이외에 니코틴산, 비오틴, 이노시톨, 엽산, 비타민 K, E 등을 생성한다.Lactic acid bacteria produce lactic acid as they grow and multiply and produce digestive enzymes such as amylase, cellulase, lipase and protease as by-products to help digest and absorb food. In addition, lactic acid bacteria stabilize vitamin B group by not only synthesizing vitamin B 1 , B 2 , B 6 , B 12 , but also inhibiting the growth of enzyme producing bacteria that destroy vitamin B1. In addition, lactic acid bacteria survive in the intestine and produce nicotinic acid, biotin, inositol, folic acid, vitamin K, E, etc. in addition to the vitamin B group.
5. 내인성 감염 억제 작용 5. Endogenous Infection Inhibition
내인성 감염의 원인은 항생제 장기 복용 시 비피더스균은 감소하고 항생제에 내성이 생기기 쉬운 대장균, 녹농균, 박테로이디스 등 잠재성 병원균이 증식하기 때문이다. 이때 면역계가 약해지거나(과로, 스트레스, 감기 등의 이유로) 기능에 이상이 생기면 이들 잠재성 병원균과 외부 침입한 병원균이 활동을 시작하여 여러 가지 질병의 증상이 나타낸다. 이때 항생제를 복용하는 치료법을 선택하면 항생제에 대한 내성이 없는 장내의 유익한 균 역시 같이 사멸하여 그 수가 감소하는 부작용이 생긴다. 따라서 규칙적으로 유산균을 섭취함으로써 장내 세균의 균형을 유지하면 감염성 질병의 발병율을 낮출 수 있어 건강한 삶을 유지할 수 있다.The cause of endogenous infections is that long-term antibiotics reduce bifidus bacteria and proliferate latent pathogens such as Escherichia coli, Pseudomonas aeruginosa, and Bacteroides, which are susceptible to antibiotic resistance. At this time, if the immune system is weakened (overwork, stress, cold, etc.) or a malfunction occurs, these latent pathogens and externally invading pathogens are active to show the symptoms of various diseases. At this time, if you choose to take antibiotics, the beneficial bacteria in the intestine, which are not resistant to antibiotics, also die, resulting in a decrease in their number. Therefore, regular intake of lactic acid bacteria to balance the intestinal bacteria can reduce the incidence of infectious diseases can maintain a healthy life.
6. 간경화 개선 작용 6. Improvement of liver cirrhosis
간은 우리 몸에서 독성물질 해독(분해) 공장으로서 매우 중요한 기관이다. 장내 유해균이 아미노산을 암모니아 같은 독성 물질로 분해하면 간은 이를 해독하여야 한다. 장내 유해균의 활동으로 암모니아의 생성량이 증가하면 간에서 다 분해하지 못하여 간에 축적되고, 이것이 간성 혼수, 뇌종양으로 발전한다. 이를 치료하기 위해서는 장관을 세척하여 유해물질 배출하거나, 세균이 많은 결장을 잘라 내거나, 또는 암모니아 생성균의 제거를 위해 비피더스 증식 인자인 lacotse를 투여하여 독성물질의 생성을 줄여야 한다. 이때 유산균을 섭취와 더불어 간 보호제를 복용하면 큰 치료효과를 얻을 수 있다. 그러나 이런 증상까지 유발하지 않기 위해서는 꾸준히 유산균을 섭취하는 노력이 필요하다. The liver is a very important organ in our body as a detoxification plant. When intestinal harmful bacteria break down amino acids into toxic substances such as ammonia, the liver must detoxify them. When the production of ammonia increases due to the activity of harmful intestines, the liver cannot be decomposed and accumulates in the liver, which develops into hepatic coma and brain tumors. To treat this, the intestines should be washed to release harmful substances, to cut out the colon with a lot of bacteria, or to reduce the production of toxic substances by administering lacotse, a bifidus growth factor, to remove ammonia-producing bacteria. At this time, take a lactic acid bacterium in addition to taking a liver protector can get a great therapeutic effect. However, in order not to cause this symptom, it is necessary to consistently ingest the lactic acid bacteria.
7. 항암효과 7. Anticancer effect
단백질이 소화되어 아미노산이 되면 장내 유해균은 탈탄산효소의 작용을 통해 각종 아민을 형성한다. arginine, ornithine, proline, putrescine을 거쳐 piperidine으로, creatin이나 sarcosine으로부터는 메틸아민을 거쳐 dimethylamine이 만들어진다. 이들은 2급 아민으로 강력한 발암물질로 알려진 nitrosamine의 원료가 된다. 아미노산은 아니지만 대두나 난황에 많이 들어있는 레시틴은 콜린을 거쳐 dimethylamine으로 전환된다. 영국의 로우란드와 그랏소는 대장균, 박테로이드, 비피더스균, 유산균 등에 의해 발암성 물질인 nitrosamine이 발암성 없는 물질로 분해한 것을 확인하였다는 연구결과를 내놓았다. 장내 유산균은 신체 내에서 합성되어 암을 유도하는 효소인 β-glucosidase, β-glucuronidase, 7-alpha- dehydrogenase, Netroreductase, azoreductase 등과 같은 발암성 유도효소의 생성을 억제하며, 발암물질을 유산균 자신에게 부착시켜 체외로 배설하거나 발암물질을 분해하는 기능이 있다. When proteins are digested and become amino acids, the intestinal harmful bacteria form various amines through the action of decarboxylase. Dimethylamine is produced via arginine, ornithine, proline, and putrescine to piperidine, and from creatin and sarcosine to methylamine. These are secondary amines that are a source of nitrosamine, a potent carcinogen. Lecithin, which is not an amino acid but is found in soy or egg yolk, is converted to dimethylamine via choline. Lowland and Grasso of the United Kingdom reported that they confirmed that carcinogenic nitrosamine decomposed into non-carcinogenic substances by Escherichia coli, bacteroids, bifidus and lactic acid bacteria. Enteric lactic acid bacteria inhibit the production of carcinogenic inducing enzymes such as β-glucosidase, β-glucuronidase, 7-alpha-dehydrogenase, Netroreductase, and azoreductase, which are synthesized in the body and induce cancer. It is excreted in vitro or decomposes carcinogens.
8. 노화억제 작용 8. Anti-aging Action
노화의 원인에는 여러 가지 학설이 있으나 활성산소에 의한 체세포의 노화, 유해세균이 단백질, 지방을 부패시켜 만드는 유해물질에 의한 노화, 유전자 속의 생체 시계에 의한 노화 등이 있다. 유산균을 규칙적으로 섭취하면 유해 세균의 생장을 억제, 사멸시켜 유해 물질 생성 억제시키고 유익균의 수적 증가와 성장을 활발히 하여 노화가 지연된다고 한다. There are many theories about aging, but aging of somatic cells by free radicals, aging by harmful substances that cause harmful bacteria to decompose proteins and fats, and aging by biological clocks in genes. Regular ingestion of lactic acid bacteria inhibits and kills the growth of harmful bacteria, inhibits the generation of harmful substances, increases the number and growth of beneficial bacteria, and delays aging.
9. 피부 미용 효과 9. Skin beauty effect
모든 사람은 장내에서 2-5Kg의 숙변을 가지고 있으며, 이 숙변에서 유해세균이 내는 독성물질이 혈액 속으로 들어가 상대적으로 혈관의 노출이 많은 얼굴에서 그 독성이 나타나 피부트러블이 생긴다. 이러한 원인을 제거하기 위하여 유산균을 섭취하면 숙변제거에 의해 숙변 속에 존재하는 유해세균 제거 및 독성물질의 배출로 피부 미용 효과가 있다. 또한 유산균 대사물질 중에서 박테로이신이라는 천연 항생제가 피부의 여드름균, 잡균을 억제하여 얼굴의 여드름균, 잡균의 제거에 도움이 된다. 즉 유산균의 대사 물질이 모낭층과 여드름균의 생장을 억제하는 것이다. “장 나쁜 미인은 없다” 는 우리말 속담에서도 장 건강이 얼마나 중요한가를 알려준다.Everyone has 2-5Kg of stool in the intestine, and the toxic substance of harmful bacteria enters the blood in the stool, which causes the skin trouble due to its toxicity on the face with high exposure of blood vessels. Ingestion of lactic acid bacteria in order to eliminate these causes has a skin cosmetic effect by eliminating harmful bacteria present in the stool by stool removal and the discharge of toxic substances. In addition, among the lactic acid bacterium metabolites, a natural antibiotic called bacteromycin helps to remove acne and various bacteria on the face by inhibiting acne and various bacteria in the skin. That is, metabolites of lactic acid bacteria inhibit the growth of hair follicle layers and acne bacteria. The proverb “No Bad Beauty” tells us how important gut health is.
10. 유당불내증을 유발하지 않음 10. Does not cause lactose intolerance
동양인의 성인 70%가 유당불내증을 가지고 있으나, bifidobacterium과 Lactobacillus가 생산하는 유당분해 효소에 의해 장에 도달하는 유당 농도가 낮아 발효유를 마셔도 설사증상을 유발하지 않는다(유당불내증 : 우유에 들어있는 lactose를 분해하는 효소가 없어서 우유를 먹으면 소화를 못 시켜 설사증세가 나타나는 것).70% of Asian adults have lactose intolerance, but low lactose levels reached by the lactose enzymes produced by bifidobacterium and Lactobacillus do not cause diarrhea even when drinking fermented milk (Lactose intolerance: lactose in milk If you eat milk because it doesn't break down enzymes, you can't digest it.
11. 숙변제거 및 변비개선효과 11. Elimination of stool and improvement of constipation
변비는 특히 여자와 노인층에 많고 갑자기 환경을 바꾸었을 때도 잘 일어난다. 변비 중에는 장내의 부패 독성물질이 증가하고 이들 독성 물질은 장내에 흡수되어 혈액을 통하여 피부에 나쁜 영향을 미친다. 피곤, 식욕과 일에 대한 의욕의 저하, 치질 발생, 혈압의 증가 등 변비의 피해는 매우 심각하다. 비피더스에 의한 변비 개선은 원인 제거보다는 변비의 증상을 개선하여 주는 것에 있다. 비피더스균은 발효 산물로서 초산과 유산을 주로 생성하는데 이들은 장의 운동을 촉진시키는 것으로 알려져있다. 따라서 장의 운동이 활성화됨에 따라 변의 통과가 원활해져 숙변 제거와 변비증상의 완화효과를 얻게 된다.Constipation is especially common in women and the elderly and suddenly changes the environment. During constipation, toxic toxins increase in the intestine, and these toxic substances are absorbed into the intestine and adversely affect the skin through the blood. Constipation is very serious, such as tiredness, decreased appetite and work motivation, hemorrhoids, and increased blood pressure. The improvement of constipation by bifidus is to improve the symptoms of constipation rather than eliminating the cause. Bifidobacteria are fermentation products that produce acetic acid and lactic acid, which are known to promote bowel movement. Therefore, as the movement of the intestine is activated, the stool passes smoothly, and the stool removal and constipation symptoms are alleviated.
나. 비타민 B1 (화합물) [vitamin B1, 아노이린, 티아민]I. Vitamin B1 (Compound) [vitamin B1, Anoline, Thiamine]
다발성(多發性) 신경염(신경계병변), 전신무기력, 동통성 경직(疼痛性硬直)등이증상으로 나타나는 각기병을 예방하기 위해 소와 같은 반추동물(反芻動物)을 제외한 모든 동물의 사료에 꼭 필요하다.Necessary in all animal feed except ruminants such as cattle to prevent various diseases such as multiple neuritis (neurologic lesions), generalized weapons, and painful stiffness. Do.
다. 비타민 B2 (화합물) [vitamin B2, 리보플라빈]All. Vitamin B2 (Compound) [vitamin B2, Riboflavin]
유장(乳漿 : 우유의 수분), 달걀의 흰자위에 풍부하게 들어 있다. 동물에게 꼭 필요한 필수영양소로 녹색식물이나 대부분의 세균·균류 등은 비타민 B2를 합성할 수 있다. 유장과 달걀 흰자위가 황록색의 형광을 띠는 것도 비타민 B2가 존재하기 때문이다. 우유·달걀, 동물의 간이나 콩팥 등이 좋은 공급원이다. 성인의 경우 매일 1.2~1.7㎎의 비타민 B2를 필요로 한다.Whey (乳 漿: milk moisture), egg whites are abundant. Essential nutrients for animals, green plants and most bacteria and fungi can synthesize vitamin B2. Whey and egg white fluoresce yellow-green because vitamin B2 is present. Milk, eggs, animal liver and kidneys are good sources. Adults need 1.2 to 1.7 mg of vitamin B2 daily.
라. 비타민 C (화합물) [vitamin C]la. Vitamin C (Compound) [vitamin C]
동물의 특정 대사과정에 참여하며 수용성이고, 탄수화물과 유사한 화합물. 대부분의 동물은 비타민 C를 체내에서 합성할 수 있지만 인간이나 영장류 등은 피부와 점막의 출혈이 나타나는 괴혈병(壞血病)을 막기 위해 음식물로부터 섭취해야만 한다. Carbohydrate-like compounds that participate in certain metabolic processes in animals. Most animals can synthesize vitamin C in the body, but humans and primates must get it from food to prevent scurvy, which causes bleeding of the skin and mucous membranes.
마. 비타민 D (화합물) [vitamin D]hemp. Vitamin D (Compound) [vitamin D]
피부에 있는 스테롤이 자외선(태양 광선)을 받으면 생긴다. 이러한 스테롤에는 동물의 대사과정에서 생기는 7-디히드로콜레스테롤과 식물성 기름에 있는 에르고스테롤이 있다. 이 두 화합물은 태양 광선을 받으면 각각 콜레칼시페롤(비타민 D3)과 칼시페롤(에르고칼시페롤, 비타민 D2)로 전환된다. 사람의 대사과정에서는 비타민 D2와 비타민D3가 동일한 작용을 하는 데 반해 조류의 경우에는 비타민 D2가 비타민 D3보다 그 기능이 떨어진다. 따라서 가금류의 먹이에는 비타민 D3를 첨가하 는 것이 좋다.This occurs when the sterols in your skin are exposed to ultraviolet light (sun rays). These sterols include 7-dihydrocholesterol from animal metabolism and ergosterol in vegetable oils. When these two compounds receive sunlight, they are converted to cholecalciferol (vitamin D3) and calciferol (ergocalciferol, vitamin D2), respectively. In human metabolism, vitamin D2 and vitamin D3 work the same, while in birds, vitamin D2 is less functional than vitamin D3. Therefore, it is advisable to add vitamin D3 to poultry food.
바. 자일리톨 [Xylitol, 크실리톨]bar. Xylitol [Xylitol]
자일리톨(xylitol)은 알코올계의 당으로 설탕 대용품이나 치아 관리용품에 이용되는 물질이다. 화학식은 C5H12O5이다. 같은 질량의 자당과 같은 정도의 단맛이 나지만 칼로리는 자당의 40% 정도이다. 자당과 달리 충치균이 분해할 수 없기 때문에 치아를 보호하는 데에 도움을 준다. 인슐린이 소모되지 않기 때문에 당뇨병 환자의 설탕 대용으로 사용된다.Xylitol is an alcoholic sugar that is used in sugar substitutes and dental care products. The chemical formula is C5H12O5. It has the same sweetness as sucrose of the same mass, but calories are about 40% of sucrose. Unlike sucrose, caries can't break down, so it helps protect your teeth. Since insulin is not consumed, it is used as a sugar substitute for diabetics.
사. 니코틴산 [nicotinic acid, 니아신]four. Nicotinic acid [nicotinic acid, niacin]
적당량을 음식물로 섭취할 경우 펠라그라병(病), 고질적인 피부질환, 위장장애 및 신경성질환 등을 막을 수 있기 때문에 펠라그라 방지 비타민, 또는 비타민 PP(pellagrapreventive)라고도 한다. 대사과정 중에 아미드기(基)와 결합해 니코틴산 아미드(니코틴아미드 또는 니아신아미드)로 바뀌기도 한다. 비타민 B1(티아민), 비타민 B2(리보플라빈)와 마찬가지로 탄수화물 대사에서 조효소(助酵素)로 작용한다.Ingestion of appropriate amounts of pellagra disease (病), chronic skin disease, gastrointestinal disorders and neurological diseases, because it can prevent pellagra vitamin or vitamin PP (pellagrapreventive) is also called. During metabolism, it binds to an amide group and converts it into nicotinic acid amide (nicotinamide or niacinamide). Like vitamin B1 (thiamine) and vitamin B2 (riboflavin), it acts as a coenzyme in carbohydrate metabolism.
아. 아르기닌 [알기닌]Ah. Arginine [Arginine]
아르기닌(arginine)은 모든 생물체에 존재하는 조건부 필수 아미노산이다. 간에서는 체내 암모니아를 제거하기 위하여 요소의 합성과정이 일어나는데, 이때 arginine이 urea cycle에서 요소로 분해된다. arginine은 상피세포, 뇌신경세포, neutrophil(중성구), nitric oxide(산화질소) 생성에도 반드시 필요하다.Arginine is a conditional essential amino acid present in all living organisms. In the liver, urea synthesis occurs to remove ammonia in the body, where arginine is broken down into urea in the urea cycle. Arginine is also essential for the production of epithelial cells, brain neurons, neutrophils, and nitric oxide.
자. 바닐라 후레바 - 바닐라 향character. Vanilla Flavor-Vanilla Scent
이미, 이취를 없애고 고소한 맛을 증진시키는 첨가제이다.Already, it is an additive that eliminates off-flavor and enhances taste.
차. 판토텐산칼슘 (화합물) [pantothenic acid calcium]car. Pantothenic acid calcium (compound)
판토텐산은 효모나 특정 세균들의 증식 촉진물질로서 고등동물들의 장(腸)내에서 합성되는 것으로 여겨진다. 이 비타민은 특히 효모·간·신장·알 등 자연계에 널리 분포하고 있지만 동물조직에서는 유리된 상태로 존재하지 않는다.Pantothenic acid is believed to be synthesized in the gut of higher animals as a growth promoter for yeast or certain bacteria. This vitamin is widely distributed in nature such as yeast, liver, kidneys and eggs, but it is not free from animal tissues.
카. 함초Ka. Hamcho
함초의 성분은 콜린, 비테인, 다당체, 식이섬유, 각종 미네랄을 함유하고 있으며, 그 효과로는 숙변의 제거, 고혈압·저혈압을 치료, 혈액순환 개선, 축농증·신장염·관절염 등에 효과가 있다. 함초에는 화농성 염증을 치료하고 갖가지균을 죽이는 작용이 있으므로 갖가지 염증과 관절염으로 인한 수종 등을 치료한다.It contains choline, bitine, polysaccharides, dietary fiber, and various minerals. Its effects include elimination of stool, treatment of hypertension and hypotension, improvement of blood circulation, sinusitis, nephritis and arthritis. Hamcho has the effect of treating purulent inflammation and killing all kinds of bacteria, and thus treating various kinds of inflammation and arthritis.
타. 강낭콩 (식물)(P. vulgaris var. humilis)Get. Kidney Beans (Plant) (P. vulgaris var. Humilis)
콩 과에 속하는 한해살이 풀로서 열매는 단백질이 많으므로 밥에 넣어 먹기도 하고 장과 두부와 기름의 원료로 쓰며 기름을 짠 깻묵은 거름으로 중요하게 쓰 인다. As an annual herb belonging to the soybean family, the fruit is rich in protein, so it is eaten in rice, and is used as an ingredient of intestines, tofu and oil, and is used as an oily salted manure.
파. 자연산 야생콩(Glycine soja)wave. Wild soybeans (Glycine soja)
우리의 산야에는 콩의 시조인 야생콩이 지천으로 자라고 있다. 이들 야생콩에는 상기한 기능성 성분을 많이 포함하고 있으며, 우리가 노력하기에 따라서는 인체의 생리활동에 도움을 주고 인간의 많은 병을 고쳐줄 약리 성분을 이들 야생콩에서 찾아낼 수가 있을 것이다.In our sanya, wild beans, the ancestors of soybeans, are growing to the point. These wild beans contain many of the above functional ingredients, and according to our efforts, we will be able to find pharmacological ingredients in these wild beans that will help the body's physiological activities and heal many diseases in humans.
하. 미역 [Undaria pinnatifida]Ha. Seaweed [Undaria pinnatifida]
식이섬유와 칼륨, 칼슘, 요오드 등이 풍부하여 신진대사를 활발하게 하고 산후조리, 변비. 비만 예방, 철분. 칼슘 보충에 탁월하여 일찍부터 애용되어 왔다. 고려시대부터 이미 중국에 수출했다는 기록이 있다. It is rich in dietary fiber, potassium, calcium, and iodine, which helps to increase metabolism, postpartum cooking, and constipation. Obesity prevention, iron. Excellent for calcium supplementation has been a favorite since early. There is a record of exporting to China since the Goryeo Dynasty.
거. 다시마 [Laminaria japonica]roughness. Kelp [Laminaria japonica]
다시마에는 카로틴류·크산토필류·엽록소 등의 여러 가지 색소 외에 탄소동화작용으로 만들어지는 마니트·라미나린 등의 탄수화물과 세포벽의 성분인 알긴산이 많이 들어 있고, 요오드·비타민 B2·글루탐산 등의 아미노산이 들어 있다.In addition to various pigments such as carotene, xanthophylls, and chlorophyll, kelp contains many carbohydrates, such as manit and laminarin, which are made by carbon assimilation, and alginic acid, which is a component of cell walls, and amino acids such as iodine, vitamin B2, and glutamic acid. This contains.
너. 톳 [Hizikia fusiformis]you. 톳 [Hizikia fusiformis]
겨울에 자라기 시작하여 이듬해 봄이 되면 30~100㎝까지 자란다. 몸은 암수 딴 그루이고 섬유상의 헛뿌리가 나와 단단하게 바위에 붙어 자라며, 원기둥 모양으로 곧추서는데 한 번 깃털 모양으로 가지를 낸다. 번식은 유성생식과 영양번식으로 한다. 한국·중국·일본에만 분포하는데 파도의 영향을 받으며 경사가 완만하고 울퉁불퉁한 바위 위에서 무성하게 자란다. 채취하여 식용으로 쓴다.It starts to grow in winter and grows up to 30 ~ 100㎝ in spring. The body is male and female, and the fibrous roots come out and grow firmly attached to the rock. Breeding is sexual reproduction and nutritional reproduction. Distributed only in Korea, China, and Japan, it is influenced by waves and grows lushly on sloping, rugged rocks. Collect and use for food.
더. 비피더스균 Lactobacillus bifidus more. Bifidus Lactobacillus bifidus
사람의 장 속에 살고있는 젖산균이다. 이것이 부족하면 설사를 일으키기 쉽다. 사람의 건강과 이 균 사이에는 밀접한 관계가 있으며, 스트레스가 쌓이거나 병에 걸리면이 균이 감소된다. 또, 모유 영양아에는 비피더스균이 많고, 인공 영양아는 이 균의 번식이 불충분하기 때문에 설사를 일으키기 쉽다고 한다. 최근 N-아세틸글루코사민에는 비피더스균의 번식을 촉진시키는 작용이 있어 설사의 원인 치료에 유효하다는 보고가 있다. It is lactic acid bacteria living in human intestines. Lack of this is likely to cause diarrhea. There is a close relationship between human health and these organisms, which are reduced when stress builds up or becomes sick. In addition, breastfeeding infants have many bifidus bacteria, and artificial feeding infants are likely to cause diarrhea because of insufficient breeding of these bacteria. Recently, N-acetylglucosamine has been reported to be effective in treating the cause of diarrhea because it has an effect of promoting the growth of bifidus bacteria.
더. 마카(MACA)more. Maca
마카의 뿌리는 감자와 모양이 비슷하며, 알맹이 또한 감자와 비슷하다. 그리고 감자 정도밖에 자라지 못하는 불모의 안데스 고원에서 자생하는 식물이다. 마카의 잎은 다소 시들어 있는 모습을 하고 있다. 색깔은 밝은 노랑, 진한 보라, 탁한 분홍, 파스텔 분홍 등 여러 가지가 있으며, 그다지 화려하지 않아 잡초와 같은 느낌이다. 감자밭 사이에 마카를 심으면 감자밭 사이사이로 잡초가 자라 있는 것처럼 보인다.Maca roots look like potatoes, and kernels also look like potatoes. It is a plant native to the barren Andes that grows only as much as potatoes. Maca leaves are somewhat withered. There are many colors such as bright yellow, dark purple, turquoise pink, and pastel pink. If you plant maca between potato fields, weeds appear to grow between the potato fields.
러. 프로폴리스N. Propolis
프로폴리스(propolis)는 꿀벌이 나무의 싹이나 수액과 같은 식물로부터 수집하는 수지질(樹脂質)의 혼합물이다. 꿀벌들은 이 프로폴리스를 벌집의 작은 틈을 메꾸는 데 사용하며, 이렇게 하여 유해한 미생물로부터 자신들을 보호한다. 꿀벌로부터 채취할 수 있는 다른 물질인 벌꿀이나 로열 젤리와는 달리 채취할 수 있는 양이 매우 적고, 인위적으로는 증량 또는 합성할 수 없는 귀중품으로, 예부터 민간 약품이나 강장제로서 세계 각지(특히 구미)에서 이용되어 왔다. 살균성, 항산화성, 항염 작용, 항종양 작용이 알려져 있다.Propolis is a resinous mixture that bees collect from plants such as tree buds and sap. Bees use this propolis to fill small gaps in the honeycomb, which protects them from harmful microorganisms. Unlike honey and royal jelly, other substances that can be collected from bees, they are very small and can't be artificially increased or synthesized, and have been used as folk medicines or tonics all over the world (especially in Europe and America). Has been used in. Bactericidal, antioxidant, anti-inflammatory and anti-tumor effects are known.
[실시예 1]Example 1
동결 건조된 혼합유산균 사균체를 혼합한 유산균 혼합체 0.1 중량%, 프로폴리스 2 중량%, 비타민 B1 0.1 중량%, 비타민 B2 0.1 중량%, 비타민 D 0.1 중량%, 비타민 C 0.3 중량%, 자일리톨 5 중량%, 니코틴산아미드 0.3 중량%, 아르기닌 0.3 중량%, 바닐라후레바 0.2 중량%, 펜토텐산칼슘 0.1 중량%, 함초 3 중량%, 강낭콩 66.3 중량%, 자연산 야생콩(Glycine soja) 5 중량%, 건미역 5 중량%, 건다시마 5 중량%, 건 톳 2 중량%, 단백질로 코팅된 동결건조 비피더스 균 0.1 중량%, 마카 5 중량%를 리본믹서기로 200 메쉬의 크기로 균질 혼합분말을 제조하고, 여기에 또 다시 물과 올리브유 약간을 투여하여 반죽하고, 이를 압축 장환기, 제환기, 정환기, 건조기에 순서의 과정을 거쳐 제조된다.Lactobacillus mixture mixed with lyophilized mixed Lactobacillus microorganisms 0.1%, Propolis 2%, Vitamin B1 0.1%, Vitamin B2 0.1%, Vitamin D 0.1%, Vitamin C 0.3%, Xylitol 5% , 0.3% by weight of nicotinic acid amide, 0.3% by weight arginine, 0.2% by weight vanilla flavora, 0.1% by weight pentothenate calcium, 3% by weight of seaweed, 66.3% by weight bean, 5% by weight of wild soybean (Glycine soja), 5% by weight dry seaweed %, 5% by weight of dried kelp, 2% by weight of 톳, 0.1% by weight of lyophilized bifidus coated with protein, and 5% by weight of maca were prepared using a ribbon mixer in a size of 200 mesh. Kneading by administering a little water and olive oil, it is manufactured through a sequence of processes in the compression chapter, the recirculator, the purifier, the dryer.
[비교예 1] Comparative Example 1
동결 건조된 혼합유산균을 단백질로 이중 코팅시킨 유산균 혼합체를 포함하는 비교예(포지티브 컨트롤) Comparative Example Including Lactic Acid Bacteria Blend Double Coated with Lyophilized Mixed Lactic Acid Bacteria (Positive Control)
동결 건조된 혼합유산균을 단백질로 이중 코팅시킨 유산균 혼합체 0.1 중량%, 프로폴리스 2 중량%, 비타민 B1 0.1 중량%, 비타민 B2 0.1 중량%, 비타민 D 0.1 중량%, 비타민 C 0.3 중량%, 자일리톨 5 중량%, 니코틴산아미드 0.3 중량%, 아르기닌 0.3 중량%, 바닐라후레바 0.2 중량%, 펜토텐산칼슘 0.1 중량%, 함초 3 중량%, 강낭콩 66.3 중량%, 자연산 야생콩(Glycine soja) 5 중량%, 건미역 5 중량%, 건다시마 5 중량%, 건 톳 2 중량%, 단백질로 코팅된 동결건조 비피더스 균 0.1 중량%, 마카 5 중량%를 리본믹서기로 200 메쉬의 크기로 균질 혼합분말을 제조하고, 여기에 또 다시 물과 올리브유 약간을 투여하여 반죽하고, 이를 압축 장환기, 제환기, 정환기, 건조기에 순서의 과정을 거쳐 제조된다.Lactobacillus mixture double coated with freeze-dried mixed lactobacillus with protein, 2% by weight of propolis, 0.1% by weight of vitamin B1, 0.1% by weight of vitamin B2, 0.1% by weight of vitamin D, 0.3% by weight of vitamin C, 5% by weight of xylitol %, 0.3% by weight nicotinamide, 0.3% by weight arginine, 0.2% by weight vanilla freva, 0.1% by weight pentothenate calcium, 3% by weight of seaweed, 66.3% by weight bean, 5% by weight of wild soybean (Glycine soja), dry seaweed 5 To prepare a homogeneous mixed powder by weight of 200% by weight of the ribbon mixer, the weight percent, 5% by weight, 5% by weight, 2% by weight, lyophilized bifidus coated with protein, 5% by weight of maca. Again, a little water and olive oil is kneaded, and it is manufactured through a sequence of processes in a compression chapter, a recirculator, a purifier, and a dryer.
[비교예 2] 코팅되지 않은 유산균(생균)을 사용한 예Comparative Example 2 Example of Use of Uncoated Lactic Acid Bacteria (Probiotic)
코팅되지 않은 동결 건조된 혼합유산균(생균) 0.1 중량%, 프로폴리스 2 중량%, 비타민 B1 0.1 중량%, 비타민 B2 0.1 중량%, 비타민 D 0.1 중량%, 비타민 C 0.3 중량%, 자일리톨 5 중량%, 니코틴산아미드 0.3 중량%, 아르기닌 0.3 중량%, 바닐라후레바 0.2 중량%, 펜토텐산칼슘 0.1 중량%, 함초 3 중량%, 강낭콩 66.3 중량%, 자연산 야생콩(Glycine soja) 5 중량%, 건미역 5 중량%, 건다시마 5 중량%, 건 톳 2 중량%, 단백질로 코팅된 동결건조 비피더스 균 0.1 중량%, 마카 5 중량%를 리본믹서기로 200 메쉬의 크기로 균질 혼합분말을 제조하고, 여기에 또 다시 물과 올리브유 약간을 부가하여 반죽하고, 이를 압축 장환기, 제환기, 정환기, 건조기에 순서의 과정을 거쳐 제조된다.0.1% by weight of the uncoated lyophilized mixed lactobacillus (probiotic), 2% by weight of propolis, 0.1% by weight of vitamin B1, 0.1% by weight of vitamin B2, 0.1% by weight of vitamin D, 0.3% by weight of vitamin C, 5% by weight of xylitol, Nicotinic acid amide 0.3% by weight, arginine 0.3% by weight, vanilla flavora 0.2% by weight, calcium pentothenate 0.1% by weight, seaweed 3% by weight, kidney beans 66.3% by weight, wild soybean (Glycine soja) 5% by weight, seaweed 5% by weight , 5% by weight of dried kelp, 2% by weight of 건, 0.1% by weight of lyophilized bifidus bacteria coated with protein, and 5% by weight of maca were prepared using a ribbon mixer in a size of 200 mesh, and again, water And a little olive oil is kneaded, it is prepared through a sequence of processes in the compression chapter, the recirculator, the recirculator, the dryer.
[비교예 3] 식이섬유(강낭콩), 프로폴리스가 중심인 비교예 Comparative Example 3 Comparative Example in which dietary fiber (kidney bean) and propolis are the center
동결 건조된 혼합유산균 사균체를 혼합한 유산균 혼합체 0.1 중량%, 프로폴리스 2 중량%, 종합 비타민 1.2 중량%, 바닐라후레바 0.2 중량%, 펜토텐산칼슘 0.1 중량%, 단백질로 코팅된 동결건조 비피더스 균 0.3 중량%, 강낭콩 96.1 중량%를 리본믹서기로 200 메쉬의 크기로 균질 혼합분말을 제조하고, 여기에 또 다시 물과 올리브유 약간을 투여하여 반죽하고, 이를 압축 장환기, 제환기, 정환기, 건조기에 순서의 과정을 거쳐 제조된다.Lactobacillus mixture mixed with lyophilized mixed Lactobacillus microorganisms 0.1%, Propolis 2%, Multivitamin 1.2%, Vanillafureva 0.2% by weight, Calcium pentothenate 0.1%, Lyophilized bifidus coated with protein 0.3% by weight, kidney beans 96.1% by weight of a ribbon mixer to prepare a homogeneous mixed powder in the size of 200 mesh, and again by administering a little water and olive oil to knead it, and put it into a compression cabinet, a recirculator, a purifier, a dryer Manufactured through the process of order.
상기 실시예 1, 비교예 1 내지 비교예 3에 의하여 실험시작 1주일 이내에 제조된 환형의 건강보조식품을 연령, 성별 및 지역의 구분을 두지 않고 선별된 숙달된 패널을 각 20명을 선발하여 매일 아침과 저녁 식전에 한 티스푼의 양으로 30일간 복용하게 하여 다음과 같은 결과를 얻을 수 있었다.Each of the 20 selected members of the selected panel without the distinction of age, sex and region of the annular health supplement food prepared within one week of the experiment by Example 1, Comparative Examples 1 to 3 each day Taking one teaspoon 30 days before breakfast and dinner, the results were as follows:
[결과 1] 제품의 기호도(이용의 편리성)[Result 1] Symbol of Product (Convenience of Use)
[결과 2] 섭식 후 장내 환경의 변화(소화, 변비 등)[Result 2] Changes in the intestinal environment after feeding (digestion, constipation, etc.)
[결과 3] 섭식 후 체중의 변화[Result 3] Changes in Weight After Eating
이상에서 살펴본 바와 같이 이 발명의 실시예는 제품의 기호도에 있어서 이 발명의 구성과 거의 동일한 정도인 분말형인 비교예 1보다 우수한 효과가 있으며, 비교예 2 또는 3 보다 섭식 복용 후 장내 환경을 긍정적으로 개선되었고 또한 유산균이 장내 우점균으로써 정착하여 다이어트 효과가 있음을 알 수 있다. 더욱이, 이 발명에서 해결하고자 하는 기지의 건강보조식품의 문제점으로 판단된 유산균과 상호 협조관계에 있는 구성을 선택적으로 채택하여 유산균의 긍적적 효과를 극대화 시킬 수 있다.As described above, the embodiment of the present invention has a superior effect than Comparative Example 1 in powder form, which is almost the same as the constitution of the present invention in the degree of preference of the product, and has a positive effect on the intestinal environment after taking the feeding than Comparative Example 2 or 3. It was also found that lactic acid bacteria had a dietary effect by being settled as intestinal dominant bacteria. Moreover, by selectively adopting a composition in mutual cooperation with the lactic acid bacteria determined to be a problem of the known health supplement food to be solved in the present invention can maximize the positive effect of the lactic acid bacteria.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080096569A KR20100037309A (en) | 2008-10-01 | 2008-10-01 | Pill type manufacturing method of health supporting food |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080096569A KR20100037309A (en) | 2008-10-01 | 2008-10-01 | Pill type manufacturing method of health supporting food |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20100037309A true KR20100037309A (en) | 2010-04-09 |
Family
ID=42214539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020080096569A KR20100037309A (en) | 2008-10-01 | 2008-10-01 | Pill type manufacturing method of health supporting food |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20100037309A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012060579A3 (en) * | 2010-11-04 | 2012-08-02 | 주식회사 쎌바이오텍 | Dead lactobacillus biomass for antimicrobial use and a production method therefor |
| CN107072276A (en) * | 2014-09-01 | 2017-08-18 | 马修·乔利·瓦达科姆里 | A kind of nutraceutical of optimization |
| KR102351088B1 (en) * | 2021-04-29 | 2022-01-14 | 최지훈 | Functional composition comprising lactic acid bacteria, propolis, vitamins and collagen |
-
2008
- 2008-10-01 KR KR1020080096569A patent/KR20100037309A/en not_active Application Discontinuation
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012060579A3 (en) * | 2010-11-04 | 2012-08-02 | 주식회사 쎌바이오텍 | Dead lactobacillus biomass for antimicrobial use and a production method therefor |
| CN102725397A (en) * | 2010-11-04 | 2012-10-10 | 细胞生物技术公司 | Dead lactobacillus biomass for antimicrobial use and a production method therefor |
| CN107072276A (en) * | 2014-09-01 | 2017-08-18 | 马修·乔利·瓦达科姆里 | A kind of nutraceutical of optimization |
| KR102351088B1 (en) * | 2021-04-29 | 2022-01-14 | 최지훈 | Functional composition comprising lactic acid bacteria, propolis, vitamins and collagen |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5517215B2 (en) | Fermentation and culture method, plant fermented extract, plant fermented extract powder and blended plant fermented extract | |
| CN108272073A (en) | A kind of weight losing meal-replacing powder and preparation method thereof | |
| CN103355499B (en) | Feed addictive for improving pork quality and increasing efficiency of feed utilization and preparation thereof | |
| KR101542667B1 (en) | Manufacturing method of fermented food using rice bran and embryo and linseed | |
| CN111084381A (en) | Ketogenic nutritional meal replacement powder and application | |
| US20100003274A1 (en) | Fermented compostions having immunodulatory actions | |
| CN103798541B (en) | The fattening period pig feed of antibiotic-free | |
| KR20120107557A (en) | Rice bran fermentation extracts with chlorophyll and the manufacturing method thereof | |
| KR101539382B1 (en) | Food composition for improvement of bowel function and relief of constipation | |
| CN110771825A (en) | Comprehensive nutrition powder for reducing fat, blood sugar, blood pressure and blood fat and preparation method thereof | |
| CN109430518A (en) | A kind of novel straw biodynamic fermentation heap and preparation method thereof | |
| KR101956516B1 (en) | Chicken feed composition and preparing method thereof | |
| CN110637942A (en) | Laying hen premix rich in amino acid eggs and production method and application thereof | |
| CN107549505A (en) | A kind of health egg feedstuff and preparation method | |
| KR101611954B1 (en) | A process for the preparation of fermented minerals pills for improving intestine function and fermented minerals pills prepared therefrom | |
| CN109430519A (en) | A kind of novel straw feed bio-fermented liquid and preparation method thereof | |
| KR101426501B1 (en) | Fermentational Composition Comprising Portulaca Oleracea L. and Rice Bran and the Method of Manufacturing thereof | |
| KR101467539B1 (en) | MANUFACTURING METHOD OF FEED COMPOSITION FOR POULTRY CONTAINING Allium hookeri POWDER | |
| CN107223792A (en) | Broiler chicken feed additive and its preparation method and application | |
| CN107594084A (en) | A kind of non-resistant ecological feed formula of growing and fattening pigs | |
| KR101955775B1 (en) | Functional fermented food additive and functionality health food manufacturing method | |
| KR20100037310A (en) | Liquefied type manufacturing method of health supporting food | |
| KR20100037309A (en) | Pill type manufacturing method of health supporting food | |
| CN1246144A (en) | Clostridium butyricum having preventive and therapeutic effects on hepatopathy, and liver supporting agents, foods and feeds each containing culture medium thereof | |
| KR101945207B1 (en) | Method for manufacturing a composition for enhancing intestinal environment and composition manufactured by the method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |